Answers are grounded in this paper and cite their sources.
IMPORTANCE OF THE FIELD: Many vaccines require the use of an adjuvant to achieve immunity. So far, few adjuvants have advanced successfully through clinical trials to become part of licensed vaccines. Vaxfectin® (Vical, CA, USA) represents a next-generation adjuvant with promise as a platform technology, showing utility with both plasmid DNA (pDNA) and protein-based vaccines. AREAS COVERED IN THIS REVIEW: This review describes the chemical, physical, preclinical and clinical development of Vaxfectin for pDNA-based vaccines. Also included is the preclinical development of Vaxfectin-adjuvanted protein- and peptide-based vaccines. WHAT THE READER WILL GAIN: The reader will gain knowledge of vaccine adjuvant development from bench to bedside. TAKE HOME MESSAGE: Vaxfectin has effectively boosted the immune response against a range of pDNA-expressed pathogenic antigens in preclinical models extending from rodents to non-human primates. In the clinic, Vaxfectin-adjuvanted pDNA-based H5N1 influenza vaccines have been shown to be well tolerated and to result in durable immune responses within the predicted protective range reported for protein-based vaccines.
No takes yet. Share an insight, caveat, or question.
Sullivan et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: